Moderna Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 5,600


  • Stock Symbol
  • MRNA

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $133.40
  • (As of Friday Closing)

Moderna General Information


Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Corporate Office
  • 200 Technology Square
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Moderna Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$133.40 $134.40 $62.55 - $170.47 $51.1B 383M 3.93M -$15.65

Moderna Financials Summary

In Thousands,
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 33,438,651 31,800,693 61,919,496 94,653,071
Revenue 5,083,000 6,754,000 18,875,000 17,736,000
EBITDA (4,620,000) (3,704,000) 9,752,000 13,499,000
Net Income (5,968,000) (4,714,000) 8,362,000 12,202,000
Total Assets 16,729,000 18,426,000 25,858,000 24,669,000
Total Debt 1,237,000 1,243,000 1,200,000 916,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Moderna Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Moderna‘s full profile, request access.

Request a free trial

Moderna Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
% Owned

This information is available in the PitchBook Platform. To explore Moderna‘s full profile, request access.

Request a free trial

Moderna Comparisons

HQ Location
Total Raised
Post Valuation
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The
Drug Discovery
Cambridge, MA
5,600 As of 2023
00000000000 00.00


is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000 000000000
Cambridge, MA
0000 As of 0000
00000000 00000


esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat n
Durham, NC
000 As of 0000
000000000 00 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Moderna Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA 0000 00000 00000000 00000
BioCryst Pharmaceuticals Corporation Durham, NC 000 00.000 000000000 00 00.000
Arcturus Therapeutics Formerly VC-backed San Diego, CA 000 000.00 000000000 000.00
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
CureVac Formerly VC-backed Tubingen, Germany 0000 00.000 00000000 00.000
You’re viewing 5 of 37 competitors. Get the full list »

Moderna Patents

Moderna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10272150-B2 Combination piv3/hmpv rna vaccines Active 22-Oct-2015 0000000000 000
US-20180326045-A1 Combination piv3/hmpv rna vaccines Active 22-Oct-2015 0000000000
US-20220152178-A1 Concatemeric peptide epitope rnas Pending 30-Jul-2015 0000000000000 0
US-20190008938-A1 Concatemeric peptide epitope rnas Pending 30-Jul-2015 0000000000000 0
US-9751925-B2 Alternative nucleic acid molecules containing reduced uracil content and uses thereof Active 10-Nov-2014 C07K14/535 00
To view Moderna’s complete patent history, request access »

Moderna Executive Team (59)

Name Title Board Seat Contact Info
Stephane Bancel Chief Executive Officer & Board Member
Stephen Hoge MD President
Melanie Ivarsson Ph.D Senior Vice President & Chief Development Officer
Adrian Stone Chief Information Security Officer & Senior Vice President
Brad Miller Chief Information Officer
You’re viewing 5 of 59 executive team members. Get the full list »

Moderna Board Members (16)

Name Representing Role Since
Elizabeth Nabel MD Self Board Member 000 0000
Elizabeth Tallett Moderna Board Member 000 0000
Israel Ruiz Moderna Board Member 000 0000
Noubar Afeyan Ph.D Flagship Pioneering Chairman & Board Member 000 0000
Paul Sagan Self Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Moderna Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Moderna Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Moderna‘s full profile, request access.

Request a free trial

Moderna Investments & Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Generation Bio 23-Mar-2023 0000 0000 Biotechnology 0000 0000
OriCiro Genomics 04-Jan-2023 0000000000 0000 Biotechnology
Valera 22-Oct-2015 000000000 0000 Therapeutic Devices 00000000
Ribometrix 01-Jan-2015 000000000 00000 Drug Discovery
Onkaido 14-Jan-2014 Corporate 0000 Drug Discovery
To view Moderna’s complete investments and acquisitions history, request access »

Moderna Subsidiaries (2)

Company Name Industry Location Founded
Valera Therapeutic Devices Cambridge, MA 2015
Onkaido Drug Discovery Cambridge, MA 0000
To view Moderna’s complete subsidiaries history, request access »

Moderna ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

19.58 | Low Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,191






00 of 921






00 of 405




To view Moderna’s complete esg history, request access »

Moderna Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
Valera 22-Oct-2015 000000000 0000 Completed
  • 0000000
Onkaido 14-Jan-2014 Corporate 0000 Completed
To view Moderna’s complete exits history, request access »

Moderna FAQs

  • When was Moderna founded?

    Moderna was founded in 2010.

  • Who is the founder of Moderna?

    Kenneth Chien Ph.D is the founder of Moderna.

  • Who is the CEO of Moderna?

    Stephane Bancel is the CEO of Moderna.

  • Where is Moderna headquartered?

    Moderna is headquartered in Cambridge, MA.

  • What is the size of Moderna?

    Moderna has 5,600 total employees.

  • What industry is Moderna in?

    Moderna’s primary industry is Drug Discovery.

  • Is Moderna a private or public company?

    Moderna is a Public company.

  • What is Moderna’s stock symbol?

    The ticker symbol for Moderna is MRNA.

  • What is the current stock price of Moderna?

    As of 21-Jun-2024 the stock price of Moderna is $133.40.

  • What is the current market cap of Moderna?

    The current market capitalization of Moderna is $51.1B.

  • What is Moderna’s current revenue?

    The trailing twelve month revenue for Moderna is $5.08B.

  • Who are Moderna’s competitors?

    Sarepta Therapeutics, BioCryst Pharmaceuticals, Arcturus Therapeutics, Alnylam Pharmaceuticals, and CureVac are some of the 37 competitors of Moderna.

  • What is Moderna’s annual earnings per share (EPS)?

    Moderna’s EPS for 12 months was -$15.65.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »